The EGFR-directed monoclonal antibody, cetuximab, is one of three targeted agents approved to date by the FDA for the treatment of HNSCC, and improves survival when added to front line platinum [14]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.